Remove 2028 Remove Diabetes Remove Drug Pricing
article thumbnail

Top 20 global biopharma companies report 9.6 per cent market cap growth in Q1 2024: GlobalData

Express Pharma

Despite the ongoing uncertainties surrounding macroeconomic activities, fluctuating interest rates, and changes in the Medicare Drug Price Negotiation landscape, the top 20 global biopharma companies experienced a promising first quarter this year. billion in 2024, according to GlobalData’s Drugs Database Pharma Intelligence Center.

article thumbnail

Market cap downturn hits over half of top 20 biopharmaceutical companies in Q1 2023

Pharmaceutical Technology

increase in market capitalisation over Q1 2023, fuelled by its robust portfolio of diabetes and obesity treatments – in particular, its line of glucagon-like peptide 1 receptor agonist (GLP-1) Type 2 diabetes drugs Ozempic, Rybelsus and Victoza. Novo Nordisk reported an 18.2%